Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration on January 7, 2026, requesting De Novo classification for multiple general surgery procedures in the upper abdomen.
The submission uses data from a completed Investigational Device Exemption (IDE) clinical study (first cases completed in early 2025) and targets procedures such as gastric bypass, gastric sleeve, small bowel resection and hiatal hernia repair. A second IDE was approved in late 2025 to begin a U.S. trial in inguinal hernia repair. The OTTAVA system remains under development and is not authorized for marketing or sale.
Johnson & Johnson (NYSE: JNJ) announced positive topline Phase 2b JASMINE results for nipocalimab in systemic lupus erythematosus (SLE) on January 6, 2026. The study met its primary endpoint (percentage achieving SRI-4 at Week 24 versus placebo) and key secondary/exploratory endpoints, including signals for steroid sparing. JASMINE enrolled 228 adults in a 52-week, randomized, double-blind, placebo-controlled, dose-ranging trial. Nipocalimab's safety and tolerability were consistent with prior Phase 2 studies with no new safety signals identified. Based on these topline results, the company plans to initiate a Phase 3 program for SLE; full study data will be presented at a future medical congress.
Johnson & Johnson (NYSE: JNJ) announced a quarterly cash dividend of $1.30 per share for Q1 2026. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026.
Johnson & Johnson (NYSE: JNJ) completed the acquisition of Halda Therapeutics OpCo for $3.05 billion in cash on December 29, 2025. The deal brings a clinical-stage oral prostate cancer therapy, HLD-0915, plus earlier RIPTAC™ platform candidates for breast, lung and other solid tumors.
J&J said the acquisition will be treated as a business combination and expects a total Adjusted EPS dilution of ~$0.20, split equally between Q4 2025 and 2026 due to non-recurring equity, financing and integration charges. Full-year 2026 guidance commentary is scheduled for the January 21, 2026 earnings call.
Johnson & Johnson (NYSE: JNJ) announced on December 18, 2025 that the U.S. Food and Drug Administration approved an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for embolization of the middle meningeal artery (MMA) to treat symptomatic subacute and chronic subdural hematoma (cSDH) as an adjunct to surgery.
The approval is supported by the randomized MEMBRANE trial, which showed TRUFILL n‑BCA was superior in effectiveness to standard of care and was demonstrated to be safe for cSDH. TRUFILL n‑BCA has been used in neurovascular embolization for over 25 years, with original FDA approval in 2000.
Johnson & Johnson (NYSE: JNJ) announced FDA approval of RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), the first subcutaneous formulation for EGFR-mutated NSCLC.
Key clinical highlights: SC administration reduces infusion time to ~5 minutes, showed an ARR rate of 13% vs 66% for IV, lower VTE incidence (11% vs 18%), and PK comparability per Phase 3 PALOMA-3. Combined with LAZCLUZE, prior MARIPOSA data showed a statistically significant OS benefit (HR 0.75; 95% CI 0.61–0.92; P=0.0048) at 37.8-month median follow-up; median OS was not reached and is projected to exceed four years.
Johnson & Johnson (NYSE: JNJ) will host an investor conference call at 8:30 a.m. ET on Wednesday, January 21 to review fourth-quarter results. The call will be led by Joaquin Duato, CEO; Joseph J. Wolk, CFO; and Darren Snellgrove, VP Investor Relations, with additional executives joining the Q&A.
Investors can access the live webcast and presentation at www.investor.jnj.com. A webcast replay will be available about three hours after the call and by telephone until ~12:00 a.m. on February 4. The press release will be posted at ~6:45 a.m. ET the morning of the call. The company also notes the first-quarter 2026 date of Tuesday, April 14, 2026.
Johnson & Johnson (NYSE:JNJ) announced U.S. FDA approval on Dec 13, 2025 for AKEEGA® (niraparib + abiraterone acetate) plus prednisone for BRCA2‑mutated metastatic castration‑sensitive prostate cancer (mCSPC).
Approval was based on Phase 3 AMPLITUDE results showing AKEEGA plus ADT reduced risk of radiographic progression or death by 54% (HR 0.46; 95% CI 0.32–0.66) and delayed symptomatic progression by 59% (HR 0.41; 95% CI 0.29–0.65).
The safety profile matched known monotherapy risks; common adverse reactions (≥20%) included hematologic abnormalities, fatigue, musculoskeletal pain, and hypertension.
Johnson & Johnson (NYSE:JNJ) reported Phase 3 MajesTEC-3 results showing TECVAYLI plus DARZALEX FASPRO significantly improved survival and response versus standard RRMM regimens at nearly three years follow-up.
Key outcomes: PFS HR 0.17 (83% risk reduction; P<0.0001), OS HR 0.46 (3-year OS 83.3% vs 65.0%), higher complete response (81.8% vs 32.1%), and higher MRD-negativity (58.4% vs 17.1%).
Safety: similar Grade 3/4 TEAE rates; higher infection rates but reduced after six months with prophylaxis.
Regulatory: sBLA submitted; U.S. FDA granted Breakthrough Therapy Designation and review via RTOR.
Johnson & Johnson (NYSE: JNJ) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time. A live audio webcast will be available on Johnson & Johnson’s Investor Relations website at www.investor.jnj.com, with an archived edition published later the same day. The audio webcast replay will be available approximately 48 hours after the live event.